No CrossRef data available.
Published online by Cambridge University Press: 15 April 2020
Over the past years, opioid analgesics use to treat chronic non-cancer pain (CNCP) has greatly increased.1Despite the existence of pain guidelines2,3,4 a majority of physicians still consider non chronic pain management as a challenge.5This study evaluate the current prescription practices of step 2 (S2A) and 3 (S3A) analgesics in northeast France.
An observational and retrospective study was conducted in a random sample of 1,000 patients using a large general health insurance reimbursement database in order to evaluate: 1) most commonly prescribed analgesics; 2) the socio-demographic data of pain patients and physicians; and 3) the adherence of physicians to French guidelines, including: i) initiate analgesic treatment with the lowest dosage, ii) do not prescribe S3A to opioid naïve patient and iii) do not associate S2A with S3A.
Almost 70% percent of the patients were women aged older than 60 years. Eighty-three percent were exclusively treated with S2A, 6% exclusively received S3A and 11% received opioid S2A with S3A. Tramadol, codeine and fentanyl transdermal were the most prescribed drugs. Fifty-one percent of patients did not start the treatment at the lowest dosage and nearly 15% of the patients receiving S3A were opioid-naïve.
This study highlights that there is still a vast domain to improve clinical practice of physicians in order to shift to best practices in the field of prescription of opioids to treat CNCP.
Comments
No Comments have been published for this article.